phenylalanine and mci 9038

phenylalanine has been researched along with mci 9038 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hijikata-Okunomiya, A; Okada, Y; Okamoto, S; Okamoto, U; Wanaka, K	1
Giddings, JC; Hashimoto, M; Matsuo, O; Oiwa, K; Okada, K; Okada, Y; Okamoto, S; Ueshima, S; Yamamoto, J	1
Bozic, M; Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M; Urleb, U; Zega, A	1

Reviews

1 review(s) available for phenylalanine and mci 9038

Article	Year
Enzyme-controlling medicines: introduction. Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:6 Topics: Aminocaproic Acid; Antifibrinolytic Agents; Antithrombins; Arginine; Enzyme Inhibitors; Humans; Kallikreins; Phenylalanine; Pipecolic Acids; Sulfonamides; Tranexamic Acid	1997

Other Studies

2 other study(ies) available for phenylalanine and mci 9038

Article	Year
Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thrombosis and haemostasis, 2003, Volume: 89, Issue:5 Topics: Animals; Antibodies; Arginine; Drug Antagonism; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Kallikreins; Male; Mesenteric Arteries; Phenylalanine; Pipecolic Acids; Plasma Kallikrein; Rats; Rats, Wistar; Sulfonamides; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator; Tranexamic Acid; Urokinase-Type Plasminogen Activator	2003
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. Thrombosis and haemostasis, 2005, Volume: 93, Issue:3 Topics: Administration, Oral; Animals; Anticoagulants; Arginine; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Injections, Subcutaneous; Male; Nadroparin; Phenylalanine; Pipecolic Acids; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombophilia; Vena Cava, Inferior; Venous Thrombosis	2005

Article

Year

Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.

Thrombosis and haemostasis, 2003, Volume: 89, Issue:5

Topics: Animals; Antibodies; Arginine; Drug Antagonism; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Kallikreins; Male; Mesenteric Arteries; Phenylalanine; Pipecolic Acids; Plasma Kallikrein; Rats; Rats, Wistar; Sulfonamides; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator; Tranexamic Acid; Urokinase-Type Plasminogen Activator

2003

Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.

Thrombosis and haemostasis, 2005, Volume: 93, Issue:3

Topics: Administration, Oral; Animals; Anticoagulants; Arginine; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Injections, Subcutaneous; Male; Nadroparin; Phenylalanine; Pipecolic Acids; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombophilia; Vena Cava, Inferior; Venous Thrombosis

2005